nach oben

Current Fungal Infection Reports

Erschienen in:

01.07.2017 | Current Management of Fungal Infections (M Miceli, Section Editor)

Update on Therapeutic Drug Monitoring of Antifungals for the Prophylaxis and Treatment of Invasive Fungal Infections

verfasst von: Ilan S. Schwartz, Nathan P. Wiederhold

Erschienen in: Current Fungal Infection Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Certain antifungals used as therapy for invasive fungal disease, including the extended-spectrum triazoles, may be limited by variable pharmacokinetics and drug interactions. This is especially important when drug exposure, as measured by trough concentrations, may be linked to either efficacy or toxicity. We review the rationale, indications, and controversies in TDM of antifungals.

Recent Findings

The monitoring of voriconazole drug levels is often practiced in patients that receive this triazole based on clinical data. Posaconazole delayed-release tablets achieve higher drug exposure more consistently, necessitating reconsideration of a role for therapeutic drug monitoring. Isavuconazole has predictable population kinetics, although exposure appears to be reduced in certain groups. However, the utility of isavuconazole therapeutic drug monitoring is unknown.

Summary

Therapeutic drug monitoring is warranted for certain antifungals, while its utility is being reconsidered for others.

Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331(20):1325–30. doi:10.1056/NEJM199411173312001.CrossRefPubMed

Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–9. doi:10.1056/NEJMoa021585.CrossRefPubMed

Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519–27. doi:10.1016/S0140-6736(07)60605-9.CrossRefPubMed

Lindsay PJ, Bond SE, Norris R, Marriott DJ, Miyakis S. Posaconazole therapeutic drug monitoring in a regional hospital setting. Ther Drug Monit. 2016;38(6):804–7. doi:10.1097/FTD.0000000000000334.CrossRefPubMed

Miyakis S, van Hal SJ, Solvag CJ, Ray J, Marriott D. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. Ther Drug Monit. 2010;32(5):661–4. doi:10.1097/FTD.0b013e3181ea3de6.CrossRefPubMed

Summers KK, Hardin TC, Gore SJ, Graybill JR. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother. 1997;40(6):753–64.CrossRefPubMed

Bruggemann RJ, Middel-Baars V, de Lange DW, Colbers A, Girbes AR, Pickkers P et al. Pharmacokinetics of anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections. Antimicrob Agents Chemother. 2017;61(2):e01894-16. doi:10.1128/AAC.01894-16.

Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM, et al. Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother. 2015;59(8):4403–9. doi:10.1128/AAC.00623-15.CrossRefPubMedPubMedCentral

Muilwijk EW, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Colbers A, et al. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother. 2014;69(12):3294–9. doi:10.1093/jac/dku313.CrossRefPubMed

10.

Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162–76. doi:10.1093/jac/dkt508.CrossRefPubMed

11.

Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83(2):236–42.CrossRefPubMed

12.

Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977;11(2):244–7.CrossRefPubMedPubMedCentral

13.

Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy. 2000;46(2):86–94. doi:7260 CrossRefPubMed

14.

Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Bruggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21–22:30–40. doi:10.1016/j.drup.2015.08.001.CrossRefPubMed

15.

Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21(24):4615–26. doi:10.1200/JCO.2003.04.052.CrossRefPubMed

16.

Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56(Suppl 1):i17–22. doi:10.1093/jac/dki220.CrossRefPubMed

17.

Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97(2):135–44.CrossRefPubMed

18.

Glasmacher A, Molitor E, Hahn C, Bomba K, Ewig S, Leutner C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia. 1998;12(9):1338–43.CrossRefPubMed

19.

Kageyama S, Masuya M, Tanaka I, Oka K, Morita K, Tamaki S, et al. Plasma concentration of itraconazole and its antifungal prophylactic efficacy in patients with neutropenia after chemotherapy for acute leukemia. J Infect Chemother Off J Jpn Soc Chemother. 1999;5(4):213–6. doi:10.1007/s101569900029.CrossRef

20.

Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy. 1999;19(5):603–11.CrossRefPubMed

21.

Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol. 1997;50(6):477–80.CrossRefPubMedPubMedCentral

22.

Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42(7–8):443–51.CrossRefPubMed

23.

Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis. 2000;30(2):300–5. doi:10.1086/313654.CrossRefPubMed

24.

Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis. 2009;49(6):928–30. doi:10.1086/605499.CrossRefPubMed

25.

Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother. 2000;45(3):371–3.CrossRefPubMed

26.

Hostetler JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother. 1993;37(10):2224–7.CrossRefPubMedPubMedCentral

27.

Laverdiere M, Bow EJ, Rotstein C, Autmizguine J, Broady R, Garber G, et al. Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol. 2014;25(6):327–43.PubMedPubMedCentral

28.

Malani AN, Kerr LE, Kauffman CA. Voriconazole: how to use this antifungal agent and what to expect. Semin Respir Crit Care Med. 2015;36(5):786–95. doi:10.1055/s-0035-1562903.CrossRefPubMed

29.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326.CrossRefPubMedPubMedCentral

30.

Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012;55(3):381–90. doi:10.1093/cid/cis437.CrossRefPubMed

31.

Berge M, Guillemain R, Boussaud V, Pham MH, Chevalier P, Batisse A, et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis. 2009;11(3):211–9. doi:10.1111/j.1399-3062.2009.00384.x.CrossRefPubMed

32.

Han K, Capitano B, Bies R, Potoski BA, Husain S, Gilbert S, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother. 2010;54(10):4424–31. doi:10.1128/AAC.00504-10.CrossRefPubMedPubMedCentral

33.

Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35(5):509–13. doi:10.1038/sj.bmt.1704828.CrossRefPubMed

34.

Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109(8):1532–5. doi:10.1002/cncr.22568.CrossRefPubMed

35.

Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(9):4793–9. doi:10.1128/AAC.00626-12.CrossRefPubMedPubMedCentral

36.

Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166–72. doi:10.1128/AAC.48.6.2166-2172.2004.CrossRefPubMedPubMedCentral

37.

Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42(4):395–402.CrossRefPubMed

38.

Mulanovich V, Lewis RE, Raad II, Kontoyiannis DP. Random plasma concentrations of voriconazole decline over time. J Infect. 2007;55(5):e129–30. doi:10.1016/j.jinf.2007.07.019.CrossRefPubMed

39.

Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Biol Fate Chem. 2003;31(6):731–41.CrossRef

40.

Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–71. doi:10.1086/324620.CrossRefPubMed

41.

Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11. doi:10.1086/524669.CrossRefPubMed

42.

Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50(4):1570–2. doi:10.1128/AAC.50.4.1570-1572.2006.CrossRefPubMedPubMedCentral

43.

Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136(45–46):739–42. doi:2006/45/smw-11547 PubMed

44.

Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46(2):235–43. doi:10.1177/0091270005283837.CrossRefPubMed

45.

Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55(10):4782–8. doi:10.1128/AAC.01083-10.CrossRefPubMedPubMedCentral

46.

• Heo ST, Aitken SL, Tverdek FP, Kontoyiannis DP. How common is subsequent central nervous system toxicity in asymptomatic patients with haematologic malignancy and supratherapeutic voriconazole serum levels? Clin Microbiol Infect. 2017; doi:10.1016/j.cmi.2016.12.031. A recent single-center study that observed lower incidence of CNS toxicity associated with elevated voriconazole levels that previously reported.

47.

Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T, et al. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta Int J Clin Chem. 2013;424C:119–22. doi:10.1016/j.cca.2013.05.025.CrossRef

48.

Levine MT, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin Transpl. 2016;30(11):1377–86. doi:10.1111/ctr.12834.CrossRef

49.

Singer JP, Boker A, Metchnikoff C, Binstock M, Boettger R, Golden JA, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant. 2012;31(7):694–9. doi:10.1016/j.healun.2012.02.033.CrossRefPubMedPubMedCentral

50.

Kolaitis NA, Duffy E, Zhang A, Lo M, Barba DT, Chen M, et al. Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation. Transpl Int. 2017;30(1):41–8. doi:10.1111/tri.12865.CrossRefPubMed

51.

• Wiederhold NP, Pennick GJ, Dorsey SA, Furmaga W, Lewis JS 2nd, Patterson TF, et al. A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother. 2014;58(1):424–31. doi:10.1128/AAC.01558-13. A retrospective review of reference laboratories experience with antifungal drug levels demonstrating the variability in concenrations that can be observed in both adults and pediatric patients. CrossRefPubMedPubMedCentral

52.

Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080–7. doi:10.1093/cid/cis599.CrossRefPubMed

53.

Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59. doi:10.1056/NEJMoa061094.CrossRefPubMed

54.

Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47. doi:10.1056/NEJMoa061098.CrossRefPubMed

55.

Thompson GR 3rd, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS 2nd. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother. 2009;53(5):2223–4. doi:10.1128/AAC.00240-09.CrossRefPubMedPubMedCentral

56.

van der Elst KC, Brouwers CH, van den Heuvel ER, van Wanrooy MJ, Uges DR, van der Werf TS, et al. Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease. Ther Drug Monit. 2015;37(6):766–71. doi:10.1097/FTD.0000000000000235.CrossRefPubMed

57.

Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(6):2806–13. doi:10.1128/AAC.05900-11.CrossRefPubMedPubMedCentral

58.

Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–66. doi:10.1128/AAC.01034-08.CrossRefPubMed

59.

Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218–22.CrossRefPubMedPubMedCentral

60.

Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50(2):658–66. doi:10.1128/AAC.50.2.658-666.2006.CrossRefPubMedPubMedCentral

61.

Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47(9):2788–95.CrossRefPubMedPubMedCentral

62.

Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27(12):1627–36. doi:10.1592/phco.27.12.1627.CrossRefPubMed

63.

Zhang H, Nguyen MH, Clancy CJ, Joshi R, Zhao W, Ensor C, et al. Pharmacokinetics of posaconazole suspension in lung transplant patients with and without cystic fibrosis. Antimicrob Agents Chemother. 2016;60(6):3558–62. doi:10.1128/AAC.00424-16.CrossRefPubMedPubMedCentral

64.

Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. 2010;88(1):115–9. doi:10.1038/clpt.2010.64.CrossRefPubMed

65.

Shields RK, Clancy CJ, Vadnerkar A, Kwak EJ, Silveira FP, Massih RC, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother. 2011;55(3):1308–11. doi:10.1128/AAC.01325-10.CrossRefPubMed

66.

Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56(11):5503–10. doi:10.1128/AAC.00802-12.CrossRefPubMedPubMedCentral

67.

Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther. 2011;89(3):351–2. doi:10.1038/clpt.2010.261.CrossRefPubMed

68.

Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12. doi:10.1086/508774.CrossRefPubMed

69.

Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58(7):4020–5. doi:10.1128/AAC.02448-13.CrossRefPubMedPubMedCentral

70.

Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725–30. doi:10.1093/jac/dks268.CrossRefPubMedPubMedCentral

71.

Fule R, Amin P. Hot melt extruded amorphous solid dispersion of posaconazole with improved bioavailability: investigating drug-polymer miscibility with advanced characterisation. Biomed Res Int. 2014;2014:146781. doi:10.1155/2014/146781.CrossRefPubMedPubMedCentral

72.

Krishna G, Ma L, Martinho M, O'Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56(8):4196–201. doi:10.1128/AAC.00222-12.CrossRefPubMedPubMedCentral

73.

Kersemaekers WM, Dogterom P, Xu J, Marcantonio EE, de Greef R, Waskin H, et al. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015;59(6):3385–9. doi:10.1128/AAC.05000-14.CrossRefPubMedPubMedCentral

74.

Duarte RF, Lopez-Jimenez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother. 2014;58(10):5758–65. doi:10.1128/AAC.03050-14.CrossRefPubMedPubMedCentral

75.

Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jimenez JL, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71(3):718–26. doi:10.1093/jac/dkv380.CrossRefPubMed

76.

• Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother. 2014;58(11):6993–5. doi:10.1128/AAC.04035-14. An early single-center study that demonstrated that the concentrations of posaconazole achieved with the new delayed release tablet were significantly higher than those achieved with the oral suspension and were not associated with adverse effects. CrossRefPubMedPubMedCentral

77.

Durani U, Tosh PK, Barreto JN, Estes LL, Jannetto PJ, Tande AJ. Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension. Antimicrob Agents Chemother. 2015;59(8):4914–8. doi:10.1128/AAC.00496-15.CrossRefPubMedPubMedCentral

78.

Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, et al. Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies. Antimicrob Agents Chemother. 2015;59(8):4424–8. doi:10.1128/AAC.00581-15.CrossRefPubMedPubMedCentral

79.

• Miceli MH, Perissinotti AJ, Kauffman CA, Couriel DR. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses. 2015;58(7):432–6. doi:10.1111/myc.12339. A single-center study that reported that diarrhea and patient weight/mass may influence concentrations of posaconazole achieved with new delayed-release tablet formulation. CrossRefPubMed

80.

Pettit NN, Miceli MH, Rivera CG, Narayanan PP, Perissinotti AJ, Hsu M, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017; doi:10.1093/jac/dkx122.

81.

Parkes LO, Cheng MP, Sheppard DC. Visual hallucinations associated with high Posaconazole concentrations in serum. Antimicrob Agents Chemother. 2016;60(2):1170–1. doi:10.1128/AAC.02739-15.CrossRefPubMedPubMedCentral

82.

Martino J, Fisher BT, Bosse KR, Bagatell R. Suspected posaconazole toxicity in a pediatric oncology patient. Pediatr Blood Cancer. 2015;62(9):1682. doi:10.1002/pbc.25568.CrossRefPubMedPubMedCentral

83.

Cornely OA. Isavuconazole: is there a need for a new antifungal? J Antimicrob Chemother. 2017;72(suppl_1):i2–4. doi:10.1093/jac/dkx027.CrossRefPubMed

84.

Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9. doi:10.1016/S0140-6736(15)01159-9.CrossRefPubMed

85.

Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis. 2016;63(3):356–62. doi:10.1093/cid/ciw305.CrossRefPubMedPubMedCentral

86.

Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–37. doi:10.1016/S1473-3099(16)00071-2.CrossRefPubMed

87.

Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572–80. doi:10.5414/CP202434.CrossRefPubMed

88.

Kovanda LL, Marty FM, Maertens J, Desai AV, Lademacher C, Engelhardt M, et al. The impact of mucositis on absorption and systemic drug exposure of isavuconazole. Antimicrob Agents Chemother. 2017; doi:10.1128/AAC.00101-17.

89.

Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558–65. doi:10.1093/cid/civ571.CrossRefPubMed

90.

•• Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60(9):5483–91. doi:10.1128/AAC.02819-15. A recent study demonstrating the probability of pharmacokinetic/pharmacodynamic target attainment with the newest triazole isavuconazole. CrossRefPubMedPubMedCentral

91.

Townsend RW, Akhtar S, Alcorn H, Berg JK, Kowalski DL, Mujais S, et al. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017;73(6):669–78. doi:10.1007/s00228-017-2213-7.CrossRefPubMedPubMedCentral

92.

Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76–85. doi:10.1002/cpdd.284.CrossRefPubMed

93.

Townsend R, Dietz A, Hale C, Akhtar S, Kowalski D, Lademacher C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):44–53. doi:10.1002/cpdd.285.CrossRefPubMed

Titel: Update on Therapeutic Drug Monitoring of Antifungals for the Prophylaxis and Treatment of Invasive Fungal Infections
verfasst von: Ilan S. Schwartz
Nathan P. Wiederhold
Publikationsdatum: 01.07.2017
Verlag: Springer US
Erschienen in: Current Fungal Infection Reports / Ausgabe 3/2017
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-017-0287-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Update on Therapeutic Drug Monitoring of Antifungals for the Prophylaxis and Treatment of Invasive Fungal Infections

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Onychomycosis Laboratory Diagnosis: Review

Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis

Fungal Leukonychia and Melanonychia: a Review

Antifungal Susceptibility Testing of Candida and Cryptococcus Species and Mechanisms of Resistance: Implications for Clinical Laboratories

The Efficacy and Safety of Systemic Antifungals in Children’s Onychomycosis

Volatile Organic Compounds: Upcoming Role in Diagnosis of Invasive Mould Infections

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin